Introduction
EBV DNA-emia is a frequent event in transplant recipients, both in solid organ as well as in HSCT. 1, 2 Patients with high levels of EBV DNA-emia are at risk of post-transplant lymphoproliferative disorders (PTLD), which may take the form of a rapidly progressive and unresponsive lymphoma. 3 T-cell depletion and the use of in vivo anti-T-cell antibodies are risk factors for EBV PTLD in HSCT recipients. 4 EBV DNA-emia can be monitored by quantitative PCR; patients with EBV DNA copies o1000/10 5 cells, have a low risk of a clinical overt PTLD, and reduction in the dose of CYA is often sufficient to prevent progression. 2 In contrast, patients with EBV DNA copies in excess of 1000 are at high risk of progressing to EBV lymphoma. 2 Once PTLD has occurred, treatment with anti-CD20 antibodies (rituximab) may be effective in a proportion of patients. 5 An alternative and very effective form of treatment for PTLD is cellular therapy with EBV-specific T cells, [5] [6] [7] [8] although this requires a dedicated facility, and may not be readily available at short notice.
We have been using anti-thymocyte globulin (ATG) for many years in our unrelated transplant program, 9 which is known to be a risk factor for EBV DNA-emia. 2 Although pre-emptive treatment with rituximab is quite effective, [5] [6] [7] [8] the clinical management of EBV DNA-emia is demanding; patients are often in the outpatient department, CYA needs to be discontinued, GvHD may flare, EBV must be monitored repeatedly, one needs to give a full dose of rituximab, the infusion is not always well tolerated and may need to be repeated and patients may require hospitalization.
Prophylaxis would be another option, as reported in 2005 by the pediatric group in Monza, in children undergoing unrelated transplants for metabolic disorders. 10 In this study, children received CD34-selected grafts, ATG as GvHD prophylaxis and in vivo B-cell depletion with rituximab 375 mg/m 2 on day þ 1 after transplant to prevent EBV infection. Only one child developed EBV-PTLD, and this was the only one who did not receive prophylactic rituximab, because of the lack of parental consent. 10 Following this encouraging experience, we started a pilot study with a fixed prophylactic dose of rituximab (200 mg) given on day þ 5 after an alternative donor transplant. We chose a lower dose as compared with the Monza report, as we had no evidence that the conventional 375 mg/m 2 was necessary, and we decided to move the infusion up to day þ 5 in order not to interfere with early cellular interactions after the infusion of donor cells. Originally only patients with a underlying lymphoproliferative dis-order, especially Hodgkin's lymphoma, in whom we had seen a high incidence of PTLD, were given rituximab, and for this reason we had concurrent patients, grafted from an unrelated donor, who were not given rituximab prophylaxis. As time went by, more patients received prophylactic rituximab, and today this is has become our standard of care.
We have now retrospectively analyzed the outcome of 55 patients receiving rituximab prophylaxis on day þ 5 after an alternative donor transplant, and compared these with 68 controls not receiving prophylactic rituximab.
Patients and methods

Patients
All patients underwent transplantation in our Unit at San Martino Hospital in Genova between 2004 and 2008. All patients received rabbit ATG (Genzyme, Boston, MA, USA, 6-10 mg/kg) in the conditioning regimen, and were alive on day þ 12 after transplant. Donor and recipient characteristics are outlined in Table 1 . There was a trend for the rituximab group to be younger (P ¼ 0.03), with more lymphoproliferative disorders (P ¼ 0.02), treated in more recent years (P ¼ 0.0001). Patients were treated on our standard transplant protocols; these included a conventional conditioning regimen for most patients based on cyclophosphamide and TBI 11 or on a reduced intensity conditioning based on the combination of thiotepa and cyclophosphamide. 12 Most patients received unmanipulated BM as stem cell source, 71 vs 76% in rituximab group and in controls, respectively. EBV nuclear Ag IgG were positive in over 90% of donor and recipients, with no difference between controls and rituximab patients. All patients signed consent forms. The study was restricted to patients receiving blood or marrow transplants.
EBV load monitoring
Patients were monitored weekly by PCR, starting on day þ 15 until day þ 100. Then they were monitored at every outpatient appointment until 1 year after transplant.
The peripheral blood samples were collected in edetate (EDTA) and DNA was extracted using the QIAamp DNA blood kit (Qiagen, Hilden, Germany), then eluted in 110 ml of buffer solution. The highly purified DNA was amplified using EBV RG PCR KIT (Qiagen) that includes EBVspecific primers, encoding for the EBNA1 gene, dNTPs, the amplification buffer, the HOT START Taq 
Prophylactic rituximab
Rituximab was administered as a slow i.v. drip on day þ 5 after transplant. The fixed dose was 200 mg for all patients; these were all adults with a median body weight of 65 kg (range 39-103).
CMV monitoring
All patients were monitored twice weekly until day þ 100 for the presence of pp65-positive cells in peripheral blood by immunoperoxidase stain. CMV-positive cells were expressed as positive cells per 2 Â 10 5 cells. 13 
Statistical analysis
Patients' data were analyzed with the NCSS package (NCSS, Keysville, UT, USA). Comparisons were carried out using the w 2 -test for categorical variables and the nonparametric Mann-Whitney U-test test for continuous variables. EBV DNA-emia, TRM and relapse-related death are all expressed as cumulative incidence. Actuarial survival was calculated according to Kaplan and Meier. A multivariate Cox analysis was run with EBV DNA-emia as an end point; the variables tested were donor age (o/ Xmedian of 37 years), recipient age (o/Xmedian of 43 years) donor and recipient gender (M/F), disease (lym- 
Results
Engraftment results
Patients receiving prophylactic rituximab on day þ 5 had similar neutrophil engraftment as controls; the quality of graft function on day þ 50, þ 100 and þ 180 is shown in Table 2 . Rituximab patients had lower leukocytes counts in comparison with the control group at all time points; lymphocytes counts were lower on day þ 100 and there was a trend for lower counts on days þ 50 and þ 180 after transplant. Platelet counts, Hb and serum Ig levels were comparable, with the only exception of lower Hb levels on day þ 180 in rituximab patients. Infectious episodes were similar in the two groups.
EBV DNA-emia EBV monitoring and outcome results are shown in Table 3 . In controls, DNA-emia occurred more frequently as compared with rituximab patients (85 vs 56%; P ¼ 0.0004) at an earlier post transplant (day þ 27 vs day þ 60, P ¼ 0.002), with a higher number of EBV copies at onset (10 vs 5 copies per 10 5 cells, P ¼ 0.03) and a higher maximum number of copies during follow-up (1321 vs 91 copies per 10 5 , P ¼ 0.003). In multivariate Cox analysis, factors predicting EBV DNA-emia were the following: lack of rituximab prophylaxis (relative risk (RR) (Figure 1) . In a Cox multivariate analysis, the only predictor of reactivating EBV with copies in excess of 1000/ 10 5 cells was rituximab prophylaxis, with a RR of 4.5 for patients not receiving prophylactic rituximab (P ¼ 0.002). All patients were given pre-emtive treatment at the time they exceeded 1000 copies per 10 5 cells, as indicated in 'Patients and methods'. Two patients in the control group (2/68) vs none in rituximab prophylaxis (0/55) developed a lethal PTLD (P ¼ 0.3).
In patients receiving the fixed dose of rituximab 200 mg on day þ 5, the median weight was 65 kg; there was a trend for a lower incidence of EBV DNA-emia exceeding 1000 copies per 10 5 cells in patients weighing less than 65 kg (7%) as compared with patients weighing more than 65 kg (22%) (P ¼ 0.1).
Of the eight patients who developed DNA-emia despite rituximab on day þ 5, there were three patients with aplastic anemia and other five patients with leukemia; Table 2 Engraftment data 
Outcome
The actuarial OS was 46% for rituximab patients and 40% for controls (Figure 2 ) and the cumulative incidence of TRM 25 vs 37% (Figure 3 ). For patients with 0-999 maximum EBV copies per 10 5 cells, survival was 17/35 for controls and 26/47 in rituximab patients (P ¼ 0.5); for EBV maximum copies X1000/10 5 cells, survival was 12/33 controls vs 6/8 rituximab patients (P ¼ 0.04).
GvHD
Patients given rituximab prophylaxis on day þ 5 had less acute GvHD grade II-IV in comparison with controls; the cumulative incidence is 20 vs 38% (P ¼ 0.02) (Figure 4) . The incidence of grade III-IV acute GvHD was 9% in controls vs 5% in rituximab patients (P ¼ 0.4). Chronic GVHD (moderate-severe) developed in 17 vs 22% of controls and rituximab patients, respectively, (P ¼ 0.4).
Rituximab
A total of 33 controls received therapeutic rituximab for a total of 36 300 mg. The 55 patients on prophylactic rituximab, received 11 000 mg prophylactically and 8 of them in addition received 9000 mg as pre-emptive treatment. The total average dose of rituximab was 533 mg per patient in controls and 363 mg per patient in the prophylactic group.
CMV reactivation CMV reactivation was comparable in the two groups; 60 vs 56% (P ¼ NS). There was no episode of CMV disease in either group, as all patients were treated pre-emptively with ganciclovir or foscarnet, according to blood counts and renal function. 
Causes of death
Causes of death are outlined in Table 3 . There was a higher rate of GvHD deaths and multi-organ failure deaths in control patients. Graft failure and rejection deaths were comparable, as well as infectious complications.
Discussion
This study suggests that rituximab, given on day þ 5 after an alternative donor transplant, significantly reduces EBV DNA-emia and reduces the proportion of patients with EBV copies X1000/10 5 cells, who would be eligible for preemptive rituximab treatment. Acute GvHD is also significantly reduced in rituximab patients and there is a trend for reduced TRM.
EBV is a significant problem in patients receiving an ATG-based conditioning regimen, and we were concerned with the high rate of EBV DNA-emia we were seeing, especially in patients with lymphoid malignancies.
14 Not only were we experiencing a high rate of DNA-emia, but also a proportion of patients was progressing to develop lethal PTLD; among the first 15 patients with EBV copies X1000/10 5 cells, we lost 5 (33%) with PTLD. 14 The increased incidence of EBV DNA-emia may also have been caused by the decision to stop using high-dose IgG in the late nineties, because of its inability to reduce transplant-related complications. 15 In retrospect, this may have been a mistake; indeed a recent study on over 40 000 renal transplants showed that prophylactic i.v. Ig abrogates EBV-associated PTLD in the first year after transplant, 1 which is an extraordinary finding per se.
However, in 2004 we were anxious to reduce our EBV DNA-emia problem, and a pediatric experience had shown that rituximab could be given on day þ 1 to children, with inborn errors of metabolism, undergoing an unrelated donor transplant. 10 We started our patients with lymphoid malignancies on rituximab 200 mg on day þ 5, and were favorably impressed with the initial results. 16 We have therefore used rituximab more systematically and it is now part of our standard of care, in patients undergoing an unrelated donor transplant, whether the stem cell source is marrow, blood or cord blood.
In this study, we show that patients receiving rituximab on day þ 5 have a significantly reduced risk of EBV DNAemia as compared with controls, and a significantly lower number of EBV copies, mostly ranging from 1 to 100. This allows us to follow these patients, without modification of GvHD prophylaxis. However, the major advantage is the strong reduction of patients, with EBV copies exceeding 1000/10 5 cells, who pose a real and urgent clinical problem. Historically, we had seen a high incidence of PTLD in patients with EBV copies X1000, 14 and we were anxious to reduce this complication. In the present series, EBV DNAemia with X1000 copies per 10 5 cells, copies was 49% in controls and 14% in the rituximab group. This implied a smaller number of patients who received therapeutic rituximab at the conventional dose of 375 mg/m 2 . Indeed when calculating the average administered dose of rituximab, we could show that patients in the prophylactic group received an average of 363 mg compared with 533 mg for patients in the control group.
This protective effect on EBV DNA-emia was obtained without major drawbacks in terms of hematological engraftment and immune reconstitution. Leukocyte and lymphocyte levels were indeed lower on day þ 50, þ 100 and on þ 180 after transplant, but this was not clinically significant, as infectious episodes were comparable. Serum Ig levels on day þ 50, þ 100 and þ 180 after transplant were comparable in the two groups.
One additional effect seems to have been a reduction of acute GvHD grade II-IV, whereas chronic GvHD was comparable. A role of B cells in the generation of acute GvHD has been suggested, 17 and warrants B cell-targeted prophylaxis and therapy. Indeed other reports, following the Houston experience in follicular lymphoma 18 have shown a reduction of acute GvHD when rituximab is used as part of the conditioning regimen. [19] [20] [21] In our study, a reduction of acute GvHD was paralleled by a trend for reduced transplant mortality due to less infections (15 vs 23%) less pneumonitis (5 vs 11%) and less multiorgan failure (10 vs 21%). One question of course concerns the fixed artbitrary dose of 200 mg of rituximab, that is, do we have evidence that patients receiving a larger dose (per kg) did better? When we looked at median weight (65 kg), there was a trend for patients with weight under the median (thus, receiving a larger dose of rituximab) to develop DNA-emia X1000 copies per 10 5 cells (7 vs 22%, P ¼ 0.1) less frequently. In conclusion, rituximab may be given on day þ 5 after an ATG-based alternative donor transplant. When compared with a control group of patients in a retrospective study, it appears to reduce EBV DNA-emia and acute GvHD, and shows a trend for reduced transplant mortality. Whether this is the optimal dose or timing remains to be determined in a prospective trial.
